Terumo Aortic全球血管腔内注册研究:多臂、多中心、开放标签、前瞻性观察性注册研究方案
该注册研究旨在收集Terumo Aortic现成与定制支架移植物治疗胸腹主动脉病变的短期和长期安全性与性能数据。研究采用多臂、多中心、开放标签、前瞻性观察性设计,入组标准宽泛,按标准治疗随访长达10年。讨论指出其真实世界优势与单厂商设计等挑战。
要点
- 多臂前瞻性观察性注册研究,评估现成与定制Terumo Aortic支架移植物。
- 入组标准宽泛,按标准治疗收集真实世界证据,随访长达10年。
- 设计挑战包括中心间标准治疗差异、单厂商设计等。
核心结论
- 该方案是一个大型血管腔内注册研究,涵盖所有采用Terumo Aortic现成和定制产品治疗的主动脉病变。
- 研究将提供最新一代支架移植物的真实世界结局,并有助于回答血管腔内主动脉修复的遗留问题。
研究设计与样本
- 多臂、多中心、开放标签、前瞻性观察性注册研究,旨在获取Terumo Aortic标准与定制血管腔内装置治疗胸腹主动脉病变的短期和长期安全性与性能数据。
- 入组要求极简,按标准治疗协议收集真实世界证据,随访长达10年。
临床怎么用
- 研究结果将 inform 临床决策、支持监管合规并指导器械研发。
- 通过纳入全球多中心广泛且 minimally selected 的患者群体,反映日常临床实践,有助于弥合临床试验与真实世界结局之间的差距。
局限性
- 研究自述挑战反映其真实世界性质,包括中心与地域间标准治疗差异、对器械或技术的经验与专业水平不一、all-comer 人群可能不总是可比,以及设计仅限于单一制造商。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approval of medical devices is typically based on data from relatively small clinical studies with a highly selected patient population. Postmarket surveillance is required by regulatory bodies after approval to collect and evaluate experience gained from real world use in larger and unselected populations. Terumo Aortic is a manufacturer of off-the-shelf and custom-made stent-grafts for endovascular repair of thoracic and abdominal aortic pathologies and is assessing device performance in a large registry. METHODS: A multiarm, multicenter, open label, prospective observational registry designed to obtain both short- and long-term safety and performance data on the use of standard and custom-made Terumo Aortic endovascular devices in patients with thoracic and abdominal aortic pathologies. Eligibility requirements are minimal, and a standard-of-care protocol will ensure real-world evidence is collected as far as 10 years. DISCUSSION: Challenges to this research reflect its real-world nature such as differences in standard of care between centers and geographies, varying levels of experience and expertise with the devices or techniques, all-comer populations that may not always be comparable, and a design specifically limited to a single manufacturer. Advantages of this registry design include long-term follow-up, different modules to collect standardized outcomes across pathologies and global reach to reflect practice in many different geographies with a wide range of latest-generation endovascular devices. CONCLUSION: This protocol is a large endovascular registry of all aortic pathologies that are treated by both off-the-shelf and custom-made Terumo Aortic products. It is ambitious in scope and projection and will be part of an overall response involving patients, physicians, and manufacturers to answer the remaining questions of endovascular aortic repair, contribute to continuing improvement of the techniques and technologies, and present an accurate picture of outcomes with latest generation stent-graft devices.Clinical ImpactThis large, long-term registry will generate robust real-world evidence on the safety and performance of both standard and custom-made Terumo Aortic endovascular devices in treating thoracic and abdominal aortic pathologies. By including a broad, minimally selected patient population across diverse global centers, the study mirrors everyday clinical practice and helps bridge the gap between clinical trials and real-world outcomes. Its findings will inform clinical decision-making, support regulatory compliance, and guide ongoing device development. Ultimately, the registry aims to enhance patient care by improving the understanding of endovascular treatment effectiveness and long-term durability in heterogeneous populations.
引用
- Reijnen MMPJ, Rylski B, Millon A, et al. The Terumo Aortic Global Endovascular Registry: A Multiarm, Multicenter, Open Label, Prospective Observational Registry to Obtain Safety and Performance Data on off-the-Shelf and Custom-Made Stent-Grafts. J Endovasc Ther. 2025. PMID: 40521921. doi:10.1177/15266028251344790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。